Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Breakthrough therapy designation is likely to positively influence perceptions of emerging drugs for both oncologists and payers... Learn More
Join us live on October 1, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Come join us for an exciting one-day seminar on Global Market Access.
View the Agenda | Meet our expert speakers
September 18, 2014
Regeneron’s Eylea and Genentech’s Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD
September 17, 2014
The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn’s Disease and Ulcerative Colitis Treatment Paradigm
Continued Uptake of Branded Therapies Will Drive the Type 2 Diabetes Market to Increase from $26 Billion in 2013 to $47 Billion in 2023
Long-Acting Agents and Fixed-Dose Combinations for Type 2 Diabetes: U.S. Physician and Payer Opinion on the Benefits of Next-Generation Antidiabetic Therapies
Type 2 diabetes is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The... Read More
Biomarkers for Emerging Biologics for Severe/Refractory Asthma
The use of biomarkers and personalized medicine is at a very early stage in asthma. Although most asthma patients can... Read More
Chile: Market Access Tracker - 2014
Last Updated 21 August 2014The Chilean pharmaceutical market is the second smallest in the Latin... Read More